Scientists much closer to developing screening test for early detection of Alzheimer's disease

Atomic structure of the Alzheimer's disease Amyloid-beta protein.

They identified blood-based biological markers that are associated with the build up of a toxic protein in the brain which occurs years before symptoms appear and irreversible brain damage has occurred.

"Early detection is critical if we are to make any real difference in the battle against Alzheimer's, giving those at risk a much better chance of receiving treatment earlier, before it's too late to do much about it," said Dr Samantha Burnham from CSIRO's Preventative Health Flagship.

Alzheimer's is the leading cause of dementia. One quarter of a million Australians currently suffer from dementia and given our , this is predicted to increase to one million people by 2050.

Sophisticated mathematical models were used to analyse data from 273 participants in the Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL).

This identified nine markers that correlate with brain positron emission tomography (PET) imaging measurements of a toxic protein, amyloid beta, which deposits in the brain as plaques early in disease development.

"The progressive build up of the , amyloid beta, is one of the earliest changes in the brain associated with the development of Alzheimer's disease," said Dr Noel Faux, from the Florey Institute for Neuroscience and Mental Health.

"A recent study from the AIBL team showed that amyloid become abnormal about 17 years before dementia symptoms appear. This gives us a much longer time to intervene to try to slow disease progression if we are able to detect cases early."

Dr Burnham adds "We hope our continued research will lead to the development of a low cost, minimally invasive population based screening test for Alzheimer's."

"A blood test would be the ideal first stage to help identify many more people at risk before a diagnosis is confirmed with and or (CSF) testing."

The results have been published in the journal Molecular Psychiatry.

add to favorites email to friend print save as pdf

Related Stories

Advance towards early Alzheimer's diagnosis

Jun 18, 2008

The leader of the team that made the discovery, Professor Christopher Rowe of the Austin Hospital in Melbourne, says early diagnosis and treatment presents medical practitioners with the best opportunity to delay the onset ...

Recommended for you

Putting dementia carers in control

20 hours ago

Experts will explore how improved support and powers for people caring for loved-ones with dementia can improve quality of life for both patients and carers around the UK.

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

User comments